Rayaldee

Maintaining Balance with Rayaldee®

Rayaldee® (calcifediol) is an extended‑release oral formulation of a vitamin D prohormone that the body converts into active vitamin D3. It is the first and only U.S. FDA‑approved medicine specifically indicated to raise serum 25D and lower intact parathyroid hormone (iPTH) in adults with secondary hyperparathyroidism (SHPT) and stage 3 or 4 chronic kidney disease (CKD) with vitamin D insufficiency.

Managing SHPT with Rayaldee®

First-in-Class
Therapy

First and only extended‑ release calcifediol approved to raise 25D and lower iPTH in stage 3-4 CKD

Targeted for Pre-Dialysis CKD

Designed specifically for adults with SHPT and vitamin D insufficiency who are not on dialysis

Evidence-Backed Outcomes

Phase 3 trials and real‑world studies demostrate effective SHPT control

Expanding Global Reach

Partnered with leading renal care companies across key international markets

Visit Rayaldee Website

Vitamin D insufficiency is highly prevalent in CKD and drives secondary hyperparathyroidism, contributing to bone disease, fractures, soft‑tissue and vascular calcification, cardiovascular complications, muscle weakness and a diminished quality of life.

37M

U.S. adults estimated to have CKD¹

~17M

U.S. adults suffer from moderate CKD (Stages 3 and 4) to severe CKD (Stage 5)

~82%

Patients in the U.S. with severe CKD afflicted by SHPT²

1 in 7

U.S. adults affected by chronic kidney disease, many ultimately requiring dialysis or transplant

¹https://www.cdc.gov/kidney-disease/php/data-research/index.html ⮑

²PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC7341786/⮑